A soluble guanylate cyclase activator inhibits the progression of diabetic nephropathy in the ZSF1 rat

Journal of Pharmacology and Experimental Therapeutics

Volumn 356, Issue 3, 2016, Pages 712-719

  Boustany Kari, Carine M ^a   Harrison, Paul C ^a   Chen, Hongxing ^a   Lincoln, Kathleen A ^a   Qian, Hu Sheng ^a   Clifford, Holly ^a   Wang, Hong ^a   Zhang, Xiaomei ^a   Gueneva Boucheva, Kristina ^a   Bosanac, Todd ^a   Wong, Diane ^a   Fryer, Ryan M ^a   Richman, Jeremy G ^a   Sarko, Chris ^a   Pullen, Steven S ^a  

^a BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; BI 703704; BIOLOGICAL MARKER; CYCLIC GMP; ENALAPRIL; GUANYLATE CYCLASE ACTIVATOR; HEMOGLOBIN A1C; KIM 1 PROTEIN; PROTEIN; UNCLASSIFIED DRUG; CELL RECEPTOR; ENALAPRILAT; ENZYME ACTIVATOR; GUANYLATE CYCLASE; SOLUBLE GUANYLYL CYCLASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CELL ACTIVATION; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DOSE RESPONSE; DRUG DETERMINATION; DRUG MEGADOSE; DRUG POTENCY; DRUG STRUCTURE; EC50; GLOMERULOPATHY; GLOMERULOSCLEROSIS; HEART RATE; HEMODYNAMICS; HISTOPATHOLOGY; IC50; IN VIVO STUDY; INTERSTITIAL NEPHRITIS; KIDNEY CORTEX; KIDNEY TUBULE DISORDER; MALE; MAXIMUM PLASMA CONCENTRATION; MEAN ARTERIAL PRESSURE; METABOLISM; MULTIPLE CYCLE TREATMENT; MYOFIBROBLAST; NONHUMAN; PRIORITY JOURNAL; PROTEINURIA; RAT; RENAL PROTECTION; TREATMENT DURATION; URINARY EXCRETION; ANIMAL; CHEMISTRY; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DISEASE COURSE; ENZYMOLOGY; ZUCKER RAT;

ANIMALS; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DISEASE PROGRESSION; ENALAPRILAT; ENZYME ACTIVATORS; GUANYLATE CYCLASE; MALE; RATS; RATS, ZUCKER; RECEPTORS, CYTOPLASMIC AND NUCLEAR;

EID: 84958999538     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.115.230706     Document Type: Article

References (29)

1. An Y, Xu F, Le W, Ge Y, Zhou M, Chen H, Zeng C, Zhang H, and Liu Z (2015) Renal histologic changes and the outcome in patients with diabetic nephropathy. Nephrol Dial Transplant 30:257-266.
2. Ayala JE, Bracy DP, Julien BM, Rottman JN, Fueger PT, and Wasserman DH (2007) Chronic treatment with sildenafil improves energy balance and insulin action in high fat-fed conscious mice. Diabetes 56:1025-1033.
3. Bader R, Bader H, Grund KE, Mackensen-Haen S, Christ H, and Bohle A (1980) Structure and function of the kidney in diabetic glomerulosclerosis: correlations between morphological and functional parameters. Pathol Res Pract 167:204-216.
4. Benz K, Orth SR, Simonaviciene A, Linz W, Schindler U, Rütten H, and Amann K (2007) Blood pressure-independent effect of long-term treatment with the soluble heme-independent guanylyl cyclase activator HMR1766 on progression in a model of noninflammatory chronic renal damage. Kidney Blood Press Res 30:224-233.
5. Berry A, Bosanac T, Ginn JD, Hopkins TD, Schlyer S, Soleymanzadeh F, Westbrook J, Yu M, and Zhang Z (2013) Soluble Guanylate Cyclase Activators U.S. patent WO 2013/0203729 A1 2013 Feb 21.
6. Boerrigter G and Burnett JC, Jr (2007) Nitric oxide-independent stimulation of soluble guanylate cyclase with BAY 41-2272 in cardiovascular disease. Cardiovasc Drug Rev 25:30-45.
7. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving H-H, Remuzzi G, Snapinn SM, Zhang Z, and Shahinfar S; RENAAL Study Investigators (2001) Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345:861-869.
8. Dellamea BS, Ferreira Pinto LC, Leitao CB, Santos KG, and Santos Canani LH (2014) Endothelial nitric oxide synthase gene polymorphisms and risk of diabetic nephropathy: a systemic review and meta-analysis. BMC Med Genet 15:9:1-13.
9. de Zeeuw D, Remuzzi G, Parving H-H, Keane WF, Zhang Z, Shahinfar S, Snapinn S, Cooper ME, Mitch WE, and Brenner BM (2004) Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. Kidney Int 65:2309-2320.
10. Hanai K, Babazono T, Nyumura I, Toya K, Tanaka N, Tanaka M, Ishii A, and Iwamoto Y (2009) Asymmetric dimethylarginine is closely associated with the development and progression of nephropathy in patients with type 2 diabetes. Nephrol Dial Transplant 24:1884-1888.
11. Hodgin JB, Nair V, Zhang H, Randolph A, Harris RC, Nelson RG, Weil EJ, Cavalcoli JD, Patel JM, and Brosius FC, 3rd, et al. (2013) Identification of cross-species shared transcriptional networks of diabetic nephropathy in human and mouse glomeruli. Diabetes 62:299-308.
12. Hoffmann LS, Etzrodt J, Willkomm L, Sanyal A, Scheja L, Fischer AW, Stasch JP, Bloch W, Friebe A, Heeren J, and Pfeifer A (2015).Stimulation of soluble guanylyl cyclase protects against obesity by recruiting brown adipose tissue. Nat Commun 6: 7235.
13. Kalk P, Godes M, Relle K, Rothkegel C, Hucke A, Stasch J-P, and Hocher B (2006) NO-independent activation of soluble guanylate cyclase prevents disease progression in rats with 5/6 nephrectomy. Br J Pharmacol 148:853-859.
14. Lajer M, Tarnow L, Jorsal A, Teerlink T, Parving H-H, and Rossing P (2008) Plasma concentration of asymmetric dimethylarginine (ADMA) predicts cardiovascular morbidity and mortality in type 1 diabetic patients with diabetic nephropathy. Diabetes Care 31:747-752.
15. Lewicki JA, Brandwein HJ, Mittal CK, Arnold WP, and Murad F (1982) Properties of purified soluble guanylate cyclase activated by nitric oxide and sodium nitroprusside. J Cyclic Nucleotide Res 8:17-25.
16. Lewis EJ, Hunsicker LG, Bain RP, and Rohde RD; The Collaborative Study Group (1993) The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 329:1456-1462.
17. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, and Raz I; Collaborative Study Group (2001) Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345:851-860.
18. Ott IM, Alter ML, von Websky K, Kretschmer A, Tsuprykov O, Sharkovska Y, Krause-Relle K, Raila J, Henze A, Stasch J-P, and Hocher B (2012) Effects of stimulation of soluble guanylate cyclase on diabetic nephropathy in diabetic eNOS knockout mice on top of angiotensin II receptor blockade. PLoS One 7:e42623.
19. Persson F, Rossing P, Hovind P, Stehouwer CDA, Schalkwijk CG, Tarnow L, and Parving H-H (2008) Endothelial dysfunction and inflammation predict development of diabetic nephropathy in the Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria (IRMA 2) study. Scand J Clin Lab Invest 68:731-738.
20. Prabhakar S, Starnes J, Shi S, Lonis B, and Tran R (2007) Diabetic nephropathy is associated with oxidative stress and decreased renal nitric oxide production. J Am Soc Nephrol 18:2945-2952.
21. Saran R, Li Y, Robinson B, Ayanian J, Balkrishnan R, Bragg-Gresham J, Chen JTL, Cope E, Gipson D, He K, et al. (2015) US Renal Data System 2014 Annual Data Report: Epidemiology of Kidney Disease in the United States. Am J Kidney Disease 66 (Suppl 1):Svii, S1-S305.
22. Shibata R, Ueda S, Yamagishi S, Kaida Y, Matsumoto Y, Fukami K, Hayashida A, Matsuoka H, Kato S, and Kimoto M, et al. (2009) Involvement of asymmetric dimethylarginine (ADMA) in tubulointerstitial ischaemia in the early phase of diabetic nephropathy. Nephrol Dial Transplant 24:1162-1169.
23. Stasch J-P, Becker EM, Alonso-Alija C, Apeler H, Dembowsky K, Feurer A, Gerzer R, Minuth T, Perzborn E, and Pleiss U, et al. (2001) NO-independent regulatory site on soluble guanylate cyclase. Nature 410:212-215.
24. Stasch J-P, Dembowsky K, Perzborn E, Stahl E, and Schramm M (2002) Cardiovascular actions of a novel NO-independent guanylyl cyclase stimulator, BAY 41-8543: in vivo studies. Br J Pharmacol 135:344-355.
25. Stasch J-P, Schlossmann J, and Hocher B (2015) Renal effects of soluble guanylate cyclase stimulators and activators: a review of the preclinical evidence. Curr Opin Pharmacol 21:95-104.
26. Stasch J-P, Schmidt PM, Nedvetsky PI, Nedvetskaya TY, H S AK, Meurer S, Deile M, Taye A, Knorr A, and Lapp H, et al. (2006) Targeting the heme-oxidized nitric oxide receptor for selective vasodilatation of diseased blood vessels. J Clin Invest 116: 2552-2561.
27. Tervaert TW, Mooyaart AL, Amann K, Cohen AH, Cook HT, Drachenberg CB, Ferrario F, Fogo AB, Haas M, and de Heer E, et al.; Renal Pathology Society (2010) Pathologic classification of diabetic nephropathy. J Am Soc Nephrol 21:556-563.
28. The SOLVD Investigators (1991) Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 325:293-302.
29. Tofovic SP and Jackson EK (2003) Rat Models of the Metabolic Syndrome in Methods in Molecular Medicine 86, Renal Disease: Techniques and Protocols (Goligorsky MS ed) pp 29-36, Humana Press, Tolowa, NJ.